Detalhe da pesquisa
1.
BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells.
Oncogene
; 22(15): 2248-59, 2003 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-12700661
2.
Cyclin D2 controls B cell progenitor numbers.
J Leukoc Biol
; 74(6): 1139-43, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14612431
3.
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Blood
; 111(7): 3723-34, 2008 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18184863
4.
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
Blood
; 109(5): 2112-20, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17068153
5.
Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.
Expert Opin Ther Targets
; 8(3): 221-39, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15161429
6.
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Proc Natl Acad Sci U S A
; 101(40): 14479-84, 2004 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-15448205